Does Tiny Iovance Deserve To Ride The T-Cell Wave?

Right now, only one company is trying to develop a new type of cell therapy for cancer: Iovance Biotherapeutics, with a market cap of $1.3 billion and 80 employees, and $246 million in the bank.
Source: Forbes.com Healthcare News - Category: Pharmaceuticals Authors: Source Type: news